Male-origin microchimerism and endometrial cancer: A prospective case-cohort study

Research output: Contribution to journalJournal articlepeer-review

Standard

Male-origin microchimerism and endometrial cancer : A prospective case-cohort study. / Hallum, Sara; Petersen, Gitte Lindved; Jakobsen, Marianne Antonious; Pinborg, Anja; Kuhlmann, Caroline; Tjønneland, Anne; Kamper-Jørgensen, Mads.

In: Cancer Epidemiology, Vol. 79, 102169, 2022.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Hallum, S, Petersen, GL, Jakobsen, MA, Pinborg, A, Kuhlmann, C, Tjønneland, A & Kamper-Jørgensen, M 2022, 'Male-origin microchimerism and endometrial cancer: A prospective case-cohort study', Cancer Epidemiology, vol. 79, 102169. https://doi.org/10.1016/j.canep.2022.102169

APA

Hallum, S., Petersen, G. L., Jakobsen, M. A., Pinborg, A., Kuhlmann, C., Tjønneland, A., & Kamper-Jørgensen, M. (2022). Male-origin microchimerism and endometrial cancer: A prospective case-cohort study. Cancer Epidemiology, 79, [102169]. https://doi.org/10.1016/j.canep.2022.102169

Vancouver

Hallum S, Petersen GL, Jakobsen MA, Pinborg A, Kuhlmann C, Tjønneland A et al. Male-origin microchimerism and endometrial cancer: A prospective case-cohort study. Cancer Epidemiology. 2022;79. 102169. https://doi.org/10.1016/j.canep.2022.102169

Author

Hallum, Sara ; Petersen, Gitte Lindved ; Jakobsen, Marianne Antonious ; Pinborg, Anja ; Kuhlmann, Caroline ; Tjønneland, Anne ; Kamper-Jørgensen, Mads. / Male-origin microchimerism and endometrial cancer : A prospective case-cohort study. In: Cancer Epidemiology. 2022 ; Vol. 79.

Bibtex

@article{702af0f6c2334129a4b0466e4d420e5e,
title = "Male-origin microchimerism and endometrial cancer: A prospective case-cohort study",
abstract = "BACKGROUND: Many women carry male cells of presumed fetal origin-so-called male-origin microchimerism (MOM)-in their circulation and tissues. Studies have found reduced risks of hormone dependent cancers, including breast and ovarian cancer, among MOM-positive women. The aim of this study was to investigate the association between MOM and endometrial cancer.METHODS: We designed a prospective case-cohort study including 76 cases and 505 controls from the Diet, Cancer and Health cohort aged 50-64 years and cancer-free at enrolment in 1993-1997. We analyzed blood samples for the presence of Y-chromosome (DYS14). We examined the association between MOM and endometrial cancer in weighted Cox regression models. As a negative control outcome, we studied the association between MOM and injuries to test for spurious associations.RESULTS: We detected MOM in 65.9% controls and 54.0% cases. While we observed no overall association between MOM and endometrial cancer (HR=0.73, 95% CI: 0.47-1.15), we found a borderline significantly reduced rate of Type 1 endometrial cancer (HR=0.66, 95% CI: 0.39-1.00), but not other types of endometrial cancers (HR=1.00, 95% CI: 0.35-2.90). The reduced rate was not modified by hormonal exposure (P = 0.79). We found no association between MOM and risk of injuries (HR=0.96, 95% CI: 95% CI: 0.78-1.21).CONCLUSIONS: Our study suggests that MOM is inversely associated with Type 1 endometrial cancer, without evidence of an interaction with hormonal exposure. We encourage future research to confirm our findings.",
author = "Sara Hallum and Petersen, {Gitte Lindved} and Jakobsen, {Marianne Antonious} and Anja Pinborg and Caroline Kuhlmann and Anne Tj{\o}nneland and Mads Kamper-J{\o}rgensen",
note = "Copyright {\textcopyright} 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2022",
doi = "10.1016/j.canep.2022.102169",
language = "English",
volume = "79",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Male-origin microchimerism and endometrial cancer

T2 - A prospective case-cohort study

AU - Hallum, Sara

AU - Petersen, Gitte Lindved

AU - Jakobsen, Marianne Antonious

AU - Pinborg, Anja

AU - Kuhlmann, Caroline

AU - Tjønneland, Anne

AU - Kamper-Jørgensen, Mads

N1 - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: Many women carry male cells of presumed fetal origin-so-called male-origin microchimerism (MOM)-in their circulation and tissues. Studies have found reduced risks of hormone dependent cancers, including breast and ovarian cancer, among MOM-positive women. The aim of this study was to investigate the association between MOM and endometrial cancer.METHODS: We designed a prospective case-cohort study including 76 cases and 505 controls from the Diet, Cancer and Health cohort aged 50-64 years and cancer-free at enrolment in 1993-1997. We analyzed blood samples for the presence of Y-chromosome (DYS14). We examined the association between MOM and endometrial cancer in weighted Cox regression models. As a negative control outcome, we studied the association between MOM and injuries to test for spurious associations.RESULTS: We detected MOM in 65.9% controls and 54.0% cases. While we observed no overall association between MOM and endometrial cancer (HR=0.73, 95% CI: 0.47-1.15), we found a borderline significantly reduced rate of Type 1 endometrial cancer (HR=0.66, 95% CI: 0.39-1.00), but not other types of endometrial cancers (HR=1.00, 95% CI: 0.35-2.90). The reduced rate was not modified by hormonal exposure (P = 0.79). We found no association between MOM and risk of injuries (HR=0.96, 95% CI: 95% CI: 0.78-1.21).CONCLUSIONS: Our study suggests that MOM is inversely associated with Type 1 endometrial cancer, without evidence of an interaction with hormonal exposure. We encourage future research to confirm our findings.

AB - BACKGROUND: Many women carry male cells of presumed fetal origin-so-called male-origin microchimerism (MOM)-in their circulation and tissues. Studies have found reduced risks of hormone dependent cancers, including breast and ovarian cancer, among MOM-positive women. The aim of this study was to investigate the association between MOM and endometrial cancer.METHODS: We designed a prospective case-cohort study including 76 cases and 505 controls from the Diet, Cancer and Health cohort aged 50-64 years and cancer-free at enrolment in 1993-1997. We analyzed blood samples for the presence of Y-chromosome (DYS14). We examined the association between MOM and endometrial cancer in weighted Cox regression models. As a negative control outcome, we studied the association between MOM and injuries to test for spurious associations.RESULTS: We detected MOM in 65.9% controls and 54.0% cases. While we observed no overall association between MOM and endometrial cancer (HR=0.73, 95% CI: 0.47-1.15), we found a borderline significantly reduced rate of Type 1 endometrial cancer (HR=0.66, 95% CI: 0.39-1.00), but not other types of endometrial cancers (HR=1.00, 95% CI: 0.35-2.90). The reduced rate was not modified by hormonal exposure (P = 0.79). We found no association between MOM and risk of injuries (HR=0.96, 95% CI: 95% CI: 0.78-1.21).CONCLUSIONS: Our study suggests that MOM is inversely associated with Type 1 endometrial cancer, without evidence of an interaction with hormonal exposure. We encourage future research to confirm our findings.

U2 - 10.1016/j.canep.2022.102169

DO - 10.1016/j.canep.2022.102169

M3 - Journal article

C2 - 35526517

VL - 79

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

M1 - 102169

ER -

ID: 306099894